Search results

776 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter
Cancer service guidelines Remove Cancer service guidelines filter

Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

In development [GID-IPG10191] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Superfcial vein arterialisation and selective venous embolisation for critical limb ischaemia

In development [GID-IPG10192] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous endovascular forearm-arteriovenous fistula creation for haemodialysis access

In development [GID-IPG10193] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Tunnelled peritoneal drainage catheter insertion for treatment-resistant, recurrent ascites due to cirrhosis

In development [GID-IPG10194] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Regional nerve graft to restore corneal sensation

In development [GID-IPG10195] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis

In development [GID-IPG10196] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Insertion of aortic arch remodelling graft as an adjunct to surgical repair of acute aortic dissection

In development [GID-IPG10197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous thoracic duct embolization for chyle leak

In development [GID-IPG10201] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Focal articular prosthetic resurfacing for treating articular cartilage defects in the knee

In development [GID-IPG10202] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Transcatheter tricuspid valve reconstruction for tricuspid regurgitation

In development [GID-IPG10198] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Sternoclavicular joint replacement for arthritis

In development [GID-IPG10199] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
External electrical muscle stimulation for urinary incontinence

In development [GID-IPG10200] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

In development [GID-TA10261] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

In development [GID-TA10087] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

In development [GID-TAG526] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

In development [GID-TA10045] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Masitinib for treating amyotrophic lateral sclerosis [ID967]

In development [GID-TA10157] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

In development [GID-TA10242] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]

In development [GID-TA10047] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

In development [GID-TAG278] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mastocytosis (systemic) - masitinib [ID781]

In development [GID-TA10019] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development